ADXSHER-2 is under clinical development by Advaxis and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect ADXSHER-2’s likelihood of approval (LoA) and phase transition for Osteosarcoma took place on 06 Oct 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their ADXSHER-2 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

ADXSHER-2 overview

ADXS-HER2 (OST-HER2) is under development for the treatment of pediatric osteosarcoma. It is a HER-2/neu vaccine targets internal and external sites on the HER-2 antigen associated with aggressive breast cancer. It is developed based on Listeria technology platform. It was also under development for the treatment of HER2 expressing cancers such as metastatic breast cancer, esophageal cancer and gastric cancer.

Advaxis overview

Advaxis is a biotechnology company that focuses on the discovery, development, and commercialization of multiple cancer immunotherapies. The company develops immunotherapies based on its proprietary Lm Technology, an antigen delivery platform that activates the immune system naturally. The Lm technology uses bioengineered live attenuated Listeria monocytogenes (Lm) bacteria to stimulate cancer-fighting T cells directed against a cancer antigen. Its immunotherapy candidates are intended for the treatment of neoantigen-directed therapies, prostate cancer, and human papilloma virus-associated cancers. The company has partnerships with various biopharmaceutical companies to develop and commercialize proprietary cancer immunotherapies. Advaxis is headquartered in Princeton, New Jersey, the US.

Quick View ADXSHER-2 LOA Data

Report Segments
  • Innovator
Drug Name
  • ADXSHER-2
Administration Pathway
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.